May 4, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Grünenthal, a pharmaceutical company headquartered in Aachen in Germany, on a series of clinical single-cell based proteomics projects.
Grünenthal is a science-based, privately-owned pharmaceutical company, and has a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring Grünenthal’s new products to life. Grünenthal is a fully integrated pharmaceutical company that offers support along the entire value chain – from drug development through to commercialisation.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Their products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
Complete Omics is proud to work with Grünenthal and our mutual efforts will help bring numerous novel pain management strategies to reality.